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human life. Inadequate intake can lead to the fatal disease scurvy. Measurement of vita-
min C is used to assess nutritional status and to monitor supplementation. The goal of this
study was to develop a chromatographic method for the quantitation of vitamin C in
human plasma.
Design and methods: Samples were prepared by protein precipitation, addition of internal
standard, and reduction with dithiothreitol. Separation of ascorbic acid was accomplished
by isocratic elution on a reverse-phase column; concentration was determined by cou-
lometry. The method was validated through studies of assay linearity, sensitivity, im-
precision, accuracy, analytical specificity, and carryover.
Results: The new assay was developed using a single pump/single analytical column HPLC
system. Results correlated well with our previously used spectrophotometric method. The
analytical measurement range was 1.0–2500 mmol/L. The injection-to-injection time was
13 min. Subsequently, to increase method throughput and shorten turnaround time, a
dual LC pump system with a 2-position/10-port switching valve capable of performing
automatic alternating column regeneration was validated and implemented. The injec-
tion-to-injection time was reduced 2-fold to 6 min. The method was linear to 5000 mmol/
L; limit of quantification was 1.9 mmol/L. Total imprecision was less than 5%.
Conclusions: We have developed a robust method suitable for routine clinical measure-
ment of vitamin C in plasma specimens. The method incorporates a simplified sample
preparation and a stable, non-endogenous internal standard to specifically quantify vi-
tamin C. Faster throughput was achieved by employing an automatic alternating column
regeneration system.
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Vitamin C (L-ascorbic acid, AA) is a water-soluble micronutrient that is required for human health [1]. Deficiency of
vitamin C causes scurvy, a fatal disease first described by Hippocrates in 500 BCE. Chemically, vitamin C is an electron donor.
The vitamin C redox system consists of ascorbic acid; its oxidized form, dehydroascorbic acid (DHAA); and the free radical
intermediate, semi-dehydroascorbic acid [2]. Physiologically, vitamin C functions as a reducing agent and an enzyme co-
factor for oxygenase enzymes responsible for the biosynthesis of collagen, carnitine, norepinephrine, and some peptide
hormones, and for the metabolism of tyrosine and pyrimidines. The vitamin promotes iron absorption in the small intestine
by reducing iron to the ferrous ion (Fe2þ). The potential role of vitamin C as an antioxidant capable of protecting cells from
free radical damage and preventing cancer and other chronic diseases, as well as its ability to act as a pro-oxidant with redox
active metals and produce harmful reactive oxygen species, makes AA a frequent subject of research studies [3]. Intravenous
(IV) infusion of vitamin C is used in complementary and alternative medicine as treatment for cancer [4]. Although con-
centrations correlate with recent intake and the half-life is relatively short (10–20 d), measurement of plasma vitamin C is
used to assess nutritional status and to monitor supplementation [2].
Laboratory measurement of vitamin C is complicated by instability of the analyte. Specimens must be protected from
light and stored frozen; preservatives may be used to stabilize vitamin C prior to analysis [5]. For many years, vitamin C has
been measured by reaction with compounds such as 2,4-dinitrophenylhydrazine to form colored derivatives that are de-
tected by spectrophotometry [6]. These methods are subject to lack of specificity, limited sensitivity, and interference from
other compounds. Newer, more specific techniques utilize high performance liquid chromatography (HPLC) with fluores-
cence, ultraviolet, or electrochemical detection (ECD) [5,7]. A spectrophotometric method developed in our laboratory had
been used for plasma vitamin C analysis for decades [6]. The procedure employed a cumbersome, time-consuming sample
preparation, used hazardous concentrated sulfuric acid, and generated large amounts of biohazardous waste. Additionally,
as interferences in plasma may form reaction products similar to those of AA, indistinguishable from the analyte using a
spectrophotometric method, this assay lacked the specificity afforded by separation techniques [5]. In order to accom-
modate increasing vitamin C test volume and to improve assay specificity, the decision was made to transfer the assay to an
HPLC platform.
This study describes the development and validation of a selective and sensitive HPLC-ECD method for the measurement
of vitamin C in plasma using a standard single liquid chromatography (LC) pump as well as a high-throughput option
utilizing a dual LC pump systemwith automatic alternating column regeneration. The method reduces total analysis time to
accommodate high test volume and extends assay linearity to facilitate measurement of elevated vitamin C concentrations
found in specimens from patients receiving intravenous ascorbic acid therapy.2. Materials and methods
2.1. Chemicals and reagents
L-Ascorbic Acid (AA), disodium ethylenediamine tetraacetic acid (Na2EDTA) dihydrate, DL-dithiothreitol (DTT), meta-
phosphoric acid (MPA), monochloroacetic acid, trisodium phosphate dodecahydrate (TSP), and the internal standard 3,4-
dihydroxybenzylamine (DHBA) were purchased from Sigma-Aldrich (St. Louis, MO). Sodium hydroxide (Macron brand) was
purchased from VWR (Radnor, PA). HPLC-grade methanol was purchased from JT-Baker (Center Valley, PA). Lyophilized
vitamin C plasma controls Levels I and II were purchased from Chromsystems (Gräfelfing, Germany). NANOpure water,
obtained from a Barnstead water system, was used throughout the study.
2.2. Preparation of calibrators, internal standard, and controls
AA stock solution, 5000 mmol/L, was prepared in 5% (w/v) MPA in water and used immediately for preparation of cali-
bration standards at 5, 25, 100 and 500 mmol/L in 5% MPA. Internal standard (IS) working solution, 50 mmol/L, was prepared
by dissolving DHBA in 5% MPA. Calibration standards and IS working solution were aliquoted and stored at 70 °C. Cali-
bration curves were constructed using four calibration standards in the single-LC pump method; a fifth standard
(5000 mmol/L stock AA solution) was added in the alternating column regeneration method. Control materials were pre-
pared by reconstitution of Chromsystems lyophilized vitamin C plasma controls Level I and II in water to provide con-
centrations at or near the minimum (23 mmol/L) and maximum (114 mmol/L) of the reference interval. Aliquots of the control
solutions were stored frozen at 70 °C.
2.3. Specimens
Venous blood was collected from self-reported healthy, non-smoking adults, who were not taking medications or vi-
tamin supplements and who had fasted for 12 h. Discarded heparinized, oxalic acid-preserved, plasma specimens submitted
for testing were selected from the routine workload for use in validation experiments. Specimens were protected from light
and stored frozen at 20 °C until analysis. All specimens were de-identified and handled according to guidelines approved
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2.4. Sample preparation
Ice-cold 10% (w/v) MPA in water (200 mL) was added to 200 mL aliquots of plasma specimens and controls in 1.5-mL
opaque centrifuge tubes to precipitate proteins. Tubes were vortexed for 30 s and then centrifuged at 23,000g for 5 min at
4 °C. In a second set of tubes, 50 mL of ice-cold IS working solution and 300 mL of ice-cold 2.5g/L DTT in aqueous 0.1 M TSP
were added to 100 mL of calibration standards, controls, and specimen supernatants. Samples were incubated for 30 min at
4 °C in an ice bath. After addition of 50 mL of 10% MPA, tubes were again vortexed and centrifuged at 23,000g for 5 min at
4 °C to pellet debris. Sample aliquots were transferred to autosampler vials. All solutions and thawed samples were kept on
ice.
2.5. Instrumentation and conditions
Instrumental analysis during method development and original validation was performed on an Agilent 1200 series
HPLC system, consisting of one binary pump, a degasser, an autosampler and a temperature controlled column compart-
ment, connected to an electrochemical detection system, consisting of a model 5020 guard cell, model 5011A high sensi-
tivity dual electrode analytical cell and Coulochems III electrochemical detector (Thermo Scientific, Waltham, MA). In-
strument control and data analysis and quantitation were performed using Agilent Chemstation software, revision B.04.03-
54 (Agilent Technologies, Santa Clara, CA).
Chromatographic separation was achieved using a Synergi Hydro-RP column (100 mm3.0 mm, 2.5 mm particles, 100 Å
pores) with a Security Guard cartridge holder containing two C-18 4 mm3.0 mm cartridges (Phenomenex, Torrance, CA).
The compounds were eluted isocratically using 98.5% mobile phase A (150 mM monochloroacetic acid, 2 mM Na2EDTA, pH
3.0070.05) and 1.5% mobile phase B (100% methanol) from 0 to 1.8 min followed by a step gradient to 20% methanol (1.81–
3.2 min) and re-equilibration at 1.5% methanol to 12 min. The mobile phase flow rate was 350 mL/min; the column tem-
perature, 30 °C; and the injection volume, 5 mL. The autosampler was held at 4 °C.
For the automatic alternating column regeneration method, the HPLC system was plumbed with two binary pumps, two
degassers, an autosampler with a 40-mL sample loop, and a temperature controlled column compartment with a 2-position/
10-port switching valve. The instrument was operated in alternating column regeneration mode, i.e. as a sample was in-
jected and separated on the first column, a regeneration gradient was running on the second column. With the next in-
jection, the flow path was changed using the 10-port switching valve, and the separation proceeded on the second column
while the first column was regenerated. Chromatographic conditions were modified to elute the compounds isocratically
(pump 1) using 98.5% mobile phase A and 1.5% mobile phase B in 5 min. The column was regenerated (pump 2) using a step
gradient to 90% methanol (0.1–1.1 min) followed by re-equilibration at 1.5% methanol to 5 min
The Coulochem
s
III detector settings were as follows: the guard cell was set at a potential of 300 mV, the analytical cell
was set at 250 mV for channel 1 and 250 mV for channel 2. The full scale gain/range was 10 mA for channel 2. For both
channels, the filter time constant was 5 s, signal output voltage was 1 V, datarate was 20/s and autozero was performed at
0.5 min after the beginning of run. ESA ChemStation Driver, version 1.0.1, was used for control of the detector.
2.6. Method validation
2.6.1. Linearity, limit of quantification, and imprecision
Method linearity was evaluated by analyzing samples prepared by spiking light (ultraviolet, UV)-depleted, unpreserved
heparinized, pooled plasma with AA at 1.0, 2.5, 5.0, 10, 25, 100, 250, 500, 625, and 2500 mmol/L. Each standard was analyzed
10 times in three different runs on three separate days. The acceptance criterion for linearity was 710% of expected
concentration.
Limit of quantification (LOQ) was evaluated by analyzing samples prepared by spiking UV-depleted, unpreserved he-
parinized plasma pool with AA at 0.625, 1.0, 2.5, 5.0, and 10 mmol/L. Each pool was analyzed a total of 10 times in three
different runs on three separate days. A curve was fitted to obtain an estimate of the coefficient of variation (CV) as a
function of the mean. The LOQ was defined as the lowest concentration for which the CV was within 20% and the con-
centration for 80% of the replicates was within 20% of the target value.
Method imprecision was evaluated by analyzing two replicates per run (beginning and end of the sequence), daily, of
Level I and Level II controls for 21 days.
2.6.2. Accuracy
Accuracy was evaluated by analyzing a National Institute of Standards and Technology (NIST) Standard Reference Ma-
terial (SRM) [8] and by method comparison. Two concentrations of NIST SRM 970, preserved with MPA, were analyzed on
three separate days.
The HPLC-ECD method was compared with the vitamin C in plasma spectrophotometric assay [6] used at the time of the
new method validation. In this method, developed in-house, a protein-free filtrate of the patient specimen was prepared
using trichloroacetic acid and mixed with acid-washed charcoal, then treated with 2,4-dinitrophenylhydrazine and sulfuric
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(1) remnant specimens preserved with oxalic acid (OxA) that had been submitted for routine vitamin C testing were
analyzed by the new method after the discard date; and (2) light-protected, unpreserved specimens collected from self-
reported healthy donors were analyzed after frozen storage at 70 °C for at least 24 h to simulate processing and transport
of patient specimens for the newly developed method.
2.6.3. Analytical specificity
To assess analytical specificity, the following conditions and substances were analyzed for interfering properties: he-
molysis (hemoglobin from hemolyzed EDTA whole blood), icterus (unconjugated bilirubin), lipemia (Intralipid
s
20% fat
emulsion), dopamine, epinephrine, glucose, glutamic acid, isoascorbic acid (IAA), metanephrine, 3-methoxytyramine, ni-
cotinamide, nicotinic acid, nicotinuric acid, norepinephrine, normetanephrine, pyridoxal, pyridoxal-5′-phosphate, riboflavin,
serine, serotonin, thiamine, thiamine diphosphate, thiamine monophosphate, urea, and uric acid. Medications evaluated as
potential inferences included acetaminophen, caffeine, diphenhydramine, ibuprofen, naproxen, nicotine and its metabolites
(cotinine and trans-3-hydroxycotinine), salicylic acid, and theobromine.
All compounds were spiked into aliquots of unpreserved, heparinized plasma containing 55 mmol/L of AA. The in-sample
potential interferent concentration matched or exceeded values recommended in CLSI EP7-A2, Interference Testing in
Clinical Chemistry [9], where given. In a separate experiment, a heparinized plasma pool with a lower AA concentration
(15 mmol/L) was spiked with hemoglobin at several concentrations to determine the amount of interference for varying
amounts of hemolysis. Appropriate baseline samples were generated by spiking the plasma pool with solvents to match the
spike solutions solvents and volumes. All samples were analyzed in triplicate. Deviation from baseline (%) was calculated as
the difference between the interference sample mean measured concentration and the respective baseline sample mean
concentration divided by the baseline sample mean concentration.
2.6.4. Carryover
Carryover was evaluated as described in the EP Evaluator software. A set of High and Low samples was assayed in the
following sequence: 3 Low, 2 High, 1 Low, 2 High, 4 Low, 2 High, 1 Low, 2 High, 1 Low, 2 High, 1 Low. A 14,200 mmol/L plasma
specimen was used as the High sample. A 10 mmol/L standard solution in 5% MPA was used as the Low sample.
2.6.5. Injection reproducibility and autosampler stability
Injection reproducibility and stability of the analyte and the IS in the autosampler during the time required for full batch
(10 calibration and control samples; 48 specimens) analysis (412.5 h) were tested by injecting a set of test samples con-
sisting of 5 and 500 mmol/L calibration standards and two concentrations of quality control materials 9 times in the span of
15.4 h.
2.6.6. Collection tube type and specimen preservation study
Venous blood from 15 self-reported healthy, non-smoking adults, who were not taking medications or vitamin sup-
plements and who had fasted for 12 h, was collected into 5 types of collection containers: no additive, serum separator
(SST), sodium heparin, plasma separator (PST), and K2EDTA; and centrifuged at 2500g for 10 min within 2 h. The resulting
serum or plasma specimens were aliquoted immediately, placed on dry ice, and stored at 70 °C. Two types of aliquots
were prepared for all tube types: light-protected and otherwise unpreserved (LP) and light-protected, preserved 1:1 (v/v)
with 10% MPA (LP-MPA). Additionally, for serum and heparinized plasma specimens, 2-mL aliquots were placed into clear
tubes to which 40 mg of oxalic acid had been added as a preservative. These tubes were used for the preservation, storage,
and transport of samples submitted for routine vitamin C testing at the time of this validation. Specimens from 10 (2 males,
8 females; aged 21–55 years) of the donors were analyzed in duplicate by the HPLC-ECD method after 2.5–3 months of
storage at 70 °C.
2.6.7. Reference interval
An established reference interval was verified by analyzing 54 heparinized plasma specimens collected from self-re-
ported healthy non-smoking adult donors, who were not taking medications or vitamin supplements and who had fasted
for 12 h prior to blood collection. These specimens were prepared as described previously and stored frozen at 70 °C until
analysis.
2.6.8. Data evaluation
Statistical evaluation of the data was performed according to CLSI guidelines using EP Evaluator software, release 10
(David G. Rhoads Associates, Inc.). The results reported for the spectrophotometric method were converted from conven-
tional units (mg/dL) to molar units (mmol/L) and data analysis was performed using Deming regression.
2.6.9. Validation of the dual LC pump system with alternating column regeneration
To validate the newly developed method on the two-LC pump system with alternating column regeneration, an ab-
breviated set of experiments was performed. Method linearity and limit of quantification were evaluated by analyzing
samples prepared by spiking UV-depleted, unpreserved heparinized plasma pool with AA at 1.0, 2.5, 5, 20, 100, 500, and
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evaluated by analyzing two replicates per run of two concentrations of control material in nine runs over five days.
To establish equivalence of the two columns, a total of 96 injections of calibration standards (44), controls (24), and
heparinized plasma specimens (28) were performed on each column over 3 days. Column equivalence was assessed as bias
(%) between the two columns for AA retention times and IS (DHBA) retention times and peak areas, and using Deming
regression for AA peak areas and concentrations.
To assess the performance of the alternating column method, 40 heparinized plasma samples, stored at –70 °C for
4 months, were analyzed and the results were compared to those obtained for separate aliquots of the same samples
analyzed on the single LC pump HPLC-ECD system during the original method validation.
A simple carryover check was performed by injecting a concentrated plasma specimen (18,740 mmol/L AA) followed by
two injections of reagent blank solution (with IS only) twice.3. Results
3.1. Chromatography and electrochemical detection
Optimal electrochemical potentials for AA and DHBA were determined using hydrodynamic voltammetry (HDV). Curves
were constructed by injecting standard solutions of the compounds in duplicate into the HPLC system and plotting the
measured oxidative current (as peak area) while increasing the analytical potential (E2) in 50 mV increments. The analytical
potential E1 was held constant at 250 mV, a value 50 mV below the potential that produced AA current. The optimal
potential was 200 mV for AA and 250 mV for DHBA. As it is not practical to use different potentials for closely eluting
compounds because of long electrode equilibration times, the higher of the two optimal potentials, E2¼250 mV, was chosen
for this method. The potential for the guard cell was set at 300 mV.
AA eluted in approximately 2 min; cycle time was 13 min for analysis on the single-LC pump system and 6 min using the
dual column system. Fig. 1 shows representative chromatograms of plasma specimens analyzed on the single-LC pump
system (A) and the two-LC pump system (B, C). Vitamin C concentrations were determined from multi-point calibration
curves produced using 1/x2 weighted linear regression analysis. Representative calibration curves are shown in Fig. 2.
3.2. Linearity, limit of quantification, and imprecision
The assay was linear from 1 to 2500 mmol/L. Measured AA concentrations were plotted against expected concentrations
to give y¼0.977x–0.040; observed error 1.9% (Table 1). The LOQ could not be estimated for AA using the EP Evaluator
Sensitivity module, because the CV values for all samples were below 20%. However, three of the 10 replicates of the
0.625 mmol/L sample did not meet the 720% accuracy criterion and therefore, the LOQ was assigned as 1.0 mmol/L. Within-
run, between-day, and total imprecision for the two quality control concentrations were between 2.1% and 6.3% (Table 1).
3.3. Accuracy
The analysis of the NIST SRM 970 showed excellent agreement of the results obtained by our method with the target
values. The deviations of the mean measured AA concentration were –1.7% and –0.9% compared to NIST Level I and Level II
target concentrations, respectively (Table 1).
Comparison of results obtained using the HPLC-ECD method (Table 1) with those obtained by the spectrophotometric
method yielded Deming regression equations: y¼0.983x–8.93; Sy/x¼7.42; R¼0.9901 for discarded specimens (n¼44) and
y¼0.834x–1.08; Sy/x¼6.77; R¼0.9167 for healthy donor specimens (n¼41). A slight negative bias was observed for the
newly developed HPLC-ECD method compared to the spectrophotometric method. Method comparison plots are shown in
Fig. 3.
3.4. Analytical specificity
The conditions and substances tested for interfering properties in the analytical specificity experiment are listed in
Table 2. Hemolyzed specimens were considered acceptable for hemoglobin concentrations up to 39 mmol/L (250 mg/dL),
which exhibited a bias o15%. Only epinephrine, IAA, and uric acid produced peaks within the detection window. Epi-
nephrine and uric acid were both baseline resolved from AA and DHBA. IAA (also called erythorbic acid), an AA stereoisomer
sometimes used as an antioxidant in processed foods and frozen vegetables, coeluted with AA. All samples were assessed for
potential interferences by evaluating additional peaks in the chromatogram that coeluted with the analyte or the IS and
examining results for other chromatographic disturbances.
3.5. Carryover
Carryover was not detected at the evaluated AA concentration of 14,200 mmol/L; that is, the calculated carryover value
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Fig. 1. Representative chromatograms of patient specimens. (A) Specimen 1 on a single LC pump system and specimen 2 on a system with alternating
column regeneration: (B) column 1, (C) column 2.
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Table 1
Validation parameters – single LC pump system.
Linearity
Matrix-matched samples prepared at 1.0, 2.5, 5.0, 10, 25, 100, 250, 500, 625, and 2500 mmol/L. Analyzed 10 aliquots of
each concentration over 3 days.
The assay was linear 1–2500 mmol/L.
Deming regression: y¼0.977x–0.04; observed error 1.9%
Means (mmol/L) 1.0, 2.5, 5.0, 9.6, 24.4, 98.9, 246.9, 492.3, 622.3, 2455.0
Accuracy (%) 103.6, 99.7, 100.0, 96.3, 97.7, 98.9, 98.8, 98.5, 99.6, 98.2
Precision (CV, %) 6.9, 4.7, 3.9, 3.5, 1.4, 1.1, 0.7, 0.9, 1.3, 0.8
Limit of Quantification
(LOQ)
Matrix-matched samples prepared by spiking UV-depleted heparinized plasma with AA to 0.625, 1.0, 2.5, 5.0, and
10 mmol/L. Analyzed 10 aliquots of each concentration over 3 days.
LOQ¼1.0 mmol/L
Target Concentration
(mmol/L)
Mean Measured Concentration
(mmol/L)
Fitted CV
(%)
Recovery
(%)
0.625 0.7 12.2 111
1.0 1.0 8.9 104
2.5 2.5 5.0 100
5.0 5.0 3.5 100
10 9.6 2.9 96
Analytical Measurement
Range
1–2500 mmol/L
Imprecision
Controls were assayed in duplicate for 21 days.
Concentration
(mmol/L)
Within-run CV
(%)
Between-day CV
(%)
Total CV
(%)
23.6 5.2 3.6 6.3
117.6 2.1 3.0 3.7
Accuracy
Comparison to reference standard
Both concentrations analyzed three times on three separate days.
Target Concentration
(mmol/L)
Mean Measured
Concentration (mmol/L)
Deviation from
Target (%)
NIST SRM 970 I 8.4 8.3 1.7
NIST SRM 970 II 28.1 27.8 0.9
Method Comparison
Discarded specimens:
Specimens analyzed using current spectrophotometric method and the evaluated method.
Deming regression: y¼0.983x–8.93; Sy/x¼7.42; R¼0.9901; n¼44
Self-reported healthy donor specimens:
Specimens analyzed using current spectrophotometric method and the evaluated method.
Deming regression: y¼0.834x–1.08; Sy/x¼6.77; R¼0.9167; n¼41
Carryover No carryover observed after plasma specimen at 14,200 mmol/L concentration.
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secutive low results.3.6. Injection reproducibility and autosampler stability
Injection reproducibility was calculated as the CV (%) of AA concentrations and peak areas for the 9 injections for each of
the four test samples, and of DHBA peak areas in all 36 injections. The CV ranged from 0.5% to 1.4% for AA concentrations and
from –0.7% to 1.8% for AA peak areas. The overall injection reproducibility for DHBA was 1.3%.
The autosampler stability was measured as deviation (%) of AA concentrations and peak areas and DHBA peak areas for
each injection compared to the first injection of the respective sample. Deviation for AA concentrations ranged from –2.6%
to 3.7%, for AA peak areas from –1.7% to 5.5%, and for DHBA peak areas from –0.2% to 3.2%, signifying that both AA and DHBA
were stable in the processed samples for at least 15.4 h at 4 °C.
Fig. 3. Method comparison plots – HPLC-ECD vs. spectrophotometry. (A) Discarded specimens, (B) fresh specimens.
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Our spectrophotometric method used heparinized plasma preserved with oxalic acid as the specimen of choice. A blood
collection tube type and specimen preservation study was conducted to determine which collection tubes were acceptable
for the newly developed vitamin C assay and whether preservation additional to light protection and freezing was neces-
sary. Two sets of aliquots from each of the five tube types (serum, SST, heparinized plasma, PST, and EDTA plasma) were
prepared: light-protected (LP) and light-protected/MPA-preserved (LP-MPA). Vitamin C concentrations for both sets of
specimens were compared to results for corresponding heparinized plasma specimens preserved with oxalic acid as illu-
strated in Fig. 4. Results for SST and PST were very similar to the corresponding tube types without a separator and were
omitted from the graphs for clarity. Similar to other studies [10,11], we found that using light protection without a pre-
servative, only heparinized plasma (including PST) concentrations agreed well (deviationo10%) with those for OxA-pre-
served specimens (see Fig. 4A). Using light protection with MPA preservation, good correlation was found for heparinized
plasma and EDTA specimens, but not for serum and SST (see Fig. 4B).
Based on these results, heparinized plasma (including PST) was selected as the specimen of choice. Next, results for LP
aliquots were compared to those for LP-MPA aliquots of heparinized plasma and PST specimens to determine whether
preservation with MPA could be omitted. Results for the unpreserved specimens were slightly lower for both heparinized
plasma (–0.2% to –8.1%, mean –4.6%) and for PST (–0.8% to –6.0%, mean –4.2%). It should be noted that these samples were
analyzed 2.5–3 months after collection and therefore the AA degradation in the LP specimens was expected to be greater
than that in specimens analyzed within a few days, the time frame for actual patient samples. This assumption was con-
firmed by comparing results from LP heparinized plasma aliquots to those of LP-MPA aliquots for the reference interval
samples analyzed within 1–3 days of collection. The deviation ranged from 4.2% to 2.9%, with mean deviation –1.3%.
Consequently, light protection of specimens without a preservative was deemed adequate for the new assay. A comparison
graph is shown in Fig. 5.
3.8. Reference interval
A published reference interval in use for our spectrophotometric method (23–114 mmol/L) was verified [12]. Values for
specimens from 54 self-reported healthy adults (26 F, 28 M), aged 20–57 years, ranged from 12.0 to 93.9 mmol/L; the mean
Table 2
Potential interferents, molecular weights, recommended and actual test concentrations in plasma, and % deviations from baseline samples.
Substance M.W. (g/mol) Recommended Test Concentration Actually Tested Concentration % Dev from Baseline
Sample conditions
Hemolysis–hemoglobina 64,458 31 mmol/L 166 mmol/L 12.3%
Hemolysis–hemoglobinb 16 mmol/L 4.8%
39 mmol/L 12.5%
78 mmol/L 16.7%
Icterus–bilirubin (unconjugated) 584.66 342 mmol/L 248 mmol/L 1.6%
Lipemia–Intralipids, 20% emulsion 275 Not specified 72 mmol/L 2.1%
Endogenous compounds
Dopamine 153.18 5.87 mmol/L 131 mmol/L 0.1%
Epinephrine 183.21 0.5 nmol/L 109 mmol/L 0.4%
Glucose 180.16 55 mmol/L 56 mmol/L 0.4%
Glutamic acid 147.13 600 mmol/L 1359 mmol/L 1.4%
Isoascorbic acid 176.13 Not specified 284 mmol/L 566.4%
Metanephrine 197.23 1.5 nmol/L 1 mmol/L 0.0%
3-Methoxytyramine 167 Not specified 299 mmol/L 0.2%
Norepinephrine 169.18 4.1 nmol/L 118 mmol/L 0.0%
Normetanephrine 183.2 2.7 nmol/L 1 mmol/L 1.0%
Serine 105.09 750 mmol/L 952 mmol/L 0.3%
Serotonin 176 3.8 mmol/L 284 mmol/L 2.1%
Urea 60.06 43 mmol/L 83 mmol/L 0.9%
Uric acid 168.11 1400 mmol/L 1487 mmol/L 3.6%
Vit B1 (Thiamine) 300.81 90 mmol/L 20 mmol/L 1.2%
Vit B1 (Thiamine monophosphate) 345.34 Not specified 20 mmol/L 1.9%
Vit B1 (Thiamine diphosphate) 425.31 Not specified 20 mmol/L 1.4%
Vit B2 (Riboflavin) 376.36 150 nmol/L 2 mmol/L 2.6%
Vit B3 (Nicotinic acid) 123.11 217 mmol/L 406 mmol/L 0.2%
Vit B3 (Nicotinamide) 122.12 Not specified 409 mmol/L 0.8%
Vit B3 (Nicotinuric acid) 180.16 Not specified 278 mmol/L 0.3%
Vit B6 (Pyridoxal) 167.16 375 nmol/L 40 mmol/L 2.7%
Vit B6 (Pyridoxal-5′-phosphate) 247.14 Not specified 40 mmol/L 2.3%
Stimulants and pharmaceuticals
Acetaminophen 151.16 1324 mmol/L 331 mmol/L 3.0%
Caffeine 194.19 308 mmol/L 257 mmol/L 0.1%
Cotinine 176.22 10.8 mmol/L 567 mmol/L 0.8%
trans-3-Hydroxycotinine 192.22 Not specified 520 mmol/L 0.1%
Diphenhydramine 255.36 19.6 mmol/L 196 mmol/L 0.7%
Ibuprofen 206.29 2425 mmol/L 485 mmol/L 0.2%
Naproxen 230.26 2170 mmol/L 1563 mmol/L 1.0%
Nicotine 162.12 6.2 mmol/L 617 mmol/L 1.0%
Salicylic acid 138.12 4.34 mmol/L 362 mmol/L 0.5%
Theobromine 180.16 278 mmol/L 278 mmol/L 0.4%
a AA concentration in plasma pool 55 mmol/L.
b AA concentration in plasma pool 15 mmol/L.
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the reference interval.
3.9. Method validation results for dual LC column system with alternating column regeneration
In addition to verification of assay performance using the dual column system, linearity was extended to an upper limit
of 5000 mmol/L. Results for validation of the assay using the dual column system are summarized in Table 3.4. Discussion
In the development of the HPLC-ECD method, we followed the HPLC protocol published by Li and Franke [13], a mod-
ification of the Centers for Disease Control and Prevention (CDC) Laboratory Procedure for vitamin C using HPLC with
electrochemical detection [14], but implemented changes in the selection of analytical column and internal standard. The
Fig. 4. Collection tube type and preservation comparison. (A) Light protected serum, EDTA plasma, and heparinized plasma concentrations compared with
concentrations for heparinized plasma specimens preserved with oxalic acid; (B) Light protected/MPA preserved serum, EDTA plasma, and heparinized
plasma concentrations compared with concentrations for heparinized plasma specimens preserved with oxalic acid. Legend: Serum – red triangles and
dashed trendline, EDTA plasma – lavender diamonds and dash-and-dot trendline, heparinized plasma – green circles and solid trendline, 1:1 line – dotted.
The regression equation and coefficient of determination are listed for each set of data.
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time.
The YMC ODS-AQ HPLC column (120 Å, 2.0 mm150 mm) used in the CDC method [14] was replaced with a Phe-
nomenex Synergi Hydro-RP 100 Å, 3.0 mm100 mm, 2.5 mm particle column. As the sample cleanup in our method is
minimal (protein precipitation and 5-fold dilution of the supernatant), we opted for an LC columnwith conventional particle
size, which we find more robust for biological specimens. For IS, Li and Franke [13] used homogentisic acid, which can be
present in plasma at significant concentrations in alcaptonuria, a genetic disorder of phenylalanine and tyrosine metabo-
lism, and the CDC method employed 1-methyluric acid, which elutes long after AA and DTT. We evaluated several com-
pounds, including 3-O-ethyl-ascorbic acid and 4-hydroxy-3-methoxybenzylamine (HMBA), 5-fluorocytosine and 5-fluor-
ouracil, and selected 3,4-dihydroxybenzylamine (DHBA) as an IS. DHBA is not endogenous and elutes significantly closer to
AA and before the DTT peak. Unlike homogentisic acid, DHBA is stable under the strong basic conditions required for
reduction of DHAA to AA (results not shown), and could be added at the beginning of the sample preparation procedure
instead of after the final re-acidification step, thus providing good compensation for experimental variability.
The calibration range was extended to 5000 mmol/L to allow measurement of the high concentrations of vitamin C found in
specimens from individuals on IV ascorbic acid therapy. This treatment produces plasma concentrations above 1 mmol/L, much
greater than concentrations expected in routine specimens or for individuals on conventional vitamin supplementation.
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Fig. 5. Comparison of results for light-protected and light-protected/MPA preserved heparinized plasma specimens.
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developed HPLC methods [13–15]. To increase method throughput and shorten turnaround time, we implemented a dual LC
pump system with an automatic alternating column regeneration. The injection-to-injection time was reduced to 6 min. In
addition, the use of the dual pump system allowed diversion of excess reducing reagent to waste and washing of the LC
column “off-line” with a significantly higher percent methanol than is possible in the single LC pump setup. The mod-
ification facilitated faster equilibration of the current in the analytical cell and increased analytical column lifetime.
The newmethod affords shorter sample preparation time (from 7.5 h to 2.5 h) using less specimen volume (from 1200 mL
to 200 mL). While the analysis time increased from 0.5 to 6 h (based on a batch of 60 samples), the technologist involvement
was approximately 0.5 h for both methods: manual reading of individual cuvettes in the spectrophotometric method versus
data review in the HPLC-based method. Hence the hands-on time was reduced from 8 to 3 h. The use of concentrated
sulfuric acid was eliminated and the amount of biohazardous waste was reduced significantly. Frozen, light-protected
unpreserved heparinized plasma or light-protected PST specimens are suitable for analysis. Vitamin C in specimens collected
and stored using these conditions provides concentrations well within expected limits of biological variation (in-
traindividual biological CV 20%) [16]. The AA stereoisomer, isoascorbic acid, co-elutes with the vitamin in this method. IAA
has not been detected in human plasma or serum [15,17,18] and is not expected to occur in appreciable concentration in
specimens submitted for vitamin C analysis.
Evaluation of results for several thousand specimens submitted for testing over one year showed adequate plasma vi-
tamin C in 66.2% of specimens tested and deficient concentrations (o23 μmol/L) in 31.3%. Approximately 17% of these
specimens contained less than 11.4 μmol/L, the AA concentration associated with risk of clinical symptoms of scurvy. In
contrast, 7% of the U.S. population sampled as part of the 2003–2004 National Health and Nutrition Examination Survey
(NHANES), were significantly deficient [19]. The overall age-adjusted mean of the NHANES subjects, 51.4 μmol/L, compared
well with the mean of our small study of healthy, non-smoking adults (59.1 μmol/L), and indicates adequate intake of
vitamin C [20]. Concentrations consistent with oral (4115 μmol/L) and intravenous (41 mmol/L) supplementation were
detected in 2% and 0.5%, respectively, of specimens tested.5. Conclusions
In conclusion, we have developed, thoroughly characterized, and validated a robust method for the determination of
ascorbic acid in plasma using 3,4-dihydroxybenzylamine as a stable, non-endogenous internal standard. The assay can be
performed in a standard single-LC pump/single column configuration, or in a high-throughput mode, utilizing a two-LC
pump HPLC-ECD system with automatic alternating column regeneration.
Table 3
Validation parameters – dual LC pump method with alternating column regeneration.
Linearity
Matrix-matched samples prepared at 5.0, 10, 100, 500, and 5000 mmol/L. Analyzed 6 aliquots of each concentration over
3 days on both columns.
The assay was linear 5–5000 mmol/L.
Column 1 Column 2
Deming regression: y¼1.040x–0.48; observed
error 2.8%
y¼1.041x–0.56; observed error 2.5%
Means (mmol/L) 4.8, 19.8, 106.5, 517.6,
5310.1
5.1, 20.0, 106.5, 517.2, 5305.7
Accuracy (%) 96.9, 98.8, 106.5, 103.5,
106.2
101.4, 100.2, 106.5, 103.4, 106.1
Precision (CV, %) 3.0, 5.2, 3.5, 2.6, 1.6 4.2, 4.6, 3.7, 2.4, 1.8
Limit of Quantification
(LOQ)
Matrix-matched samples prepared by spiking UV-depleted heparinized plasma with ascorbic acid to 0.625, 1.0, 2.5, 5.0,
and 10 mmol/L. Analyzed 10 aliquots of each concentration over 3 days on both columns.
Column 1 LOQ¼1.9 mmol/L (EP Evaluator estimate)
Target Concentration
(mmol/L)
Mean Measured Con-
centration (mmol/L)
SD
(mmol/L)
Fitted CV
(%)
Accuracy
(%)
1.0 1.0 0.2 24.7 105
2.5 2.3 0.4 12.7 93
5.0 4.8 0.1 7.8 97
20.0 19.8 1.0 4.3 99
100.0 106.5 3.7 3.4 107
Column 2 LOQ¼1.0 mmol/L (assigned)
Target Concentration
(mmol/L)
Mean Measured Con-
centration (mmol/L)
SD
(mmol/L)
Fitted CV
(%)
Accuracy
(%)
1.0 1.1 0.1 17.6 108
2.5 2.3 0.3 10.4 92
5.0 4.8 0.2 7.0 95
20.0 19.8 1.0 4.7 99
100.0 106.2 4.0 4.1 106
System LOQ¼1.9 mmol/L (assigned)
Analytical Measure-
ment Range
5–5000 mmol/L
Imprecision
Controls were assayed in duplicate in nine runs over 5 days.
Column 1 Column 2
Concentration
(mmol/L)
Total CV (%) Concentration (mmol/
L)
Total CV (%)
22.9 3.0 23.0 3.2
108.6 3.3 109.4 4.3
Accuracy/Method
Comparison
Self-reported healthy donor specimens
Reference interval specimens analyzed by the single LC pump method and the evaluated method (dual LC pump).
Deming regression: y¼0.992x2.19; Sy/x¼2.37; R¼0.9898; n¼40
Carryover No carryover observed after plasma specimen at 18,740 mmol/L concentration.
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